Literature DB >> 30428092

Corneal Surface Ablation Laser Refractive Surgery for the Correction of Myopia: A Network Meta-analysis.

Daizong Wen, Ruixue Tu, Ian Flitcroft, Qinmei Wang, Yingying Huang, Benhao Song, Ayong Yu, Liang Hu, Yune Zhao, Fangjun Bao, Ye Yu, Hengli Lian, Louis Hoffart, Robert Lee Kramm, Eirini Skiadaresi, David O'Brart, Ioannis Pallikaris, John Marshall, Colm McAlinden, Jinhai Huang.   

Abstract

PURPOSE: To systematically compare the efficacy, predictability, safety, postoperative haze, pain scores, and epithelial healing time of four corneal surface ablation procedures.
METHODS: PubMed, Embase, Cochrane Library, and the U.S. trial registry were searched up to June 2018. Randomized controlled trials were selected. Efficacy (uncorrected distance visual acuity of 20/20 or better), predictability (refractive spherical equivalent within ±0.50 diopters [D] of the target), and safety (loss of two or more lines of spectacle corrected distance visual acuity) were set as primary outcome measures. Haze, pain scores, and epithelial healing time were set as secondary outcome measures.
RESULTS: Eighteen studies involving 1,423 eyes were included. According to the Grading of Recommendations Assessment, Development, and Evaluation, the quality of outcomes were moderate to high (70.6%). There were no differences in efficacy, predictability, safety, haze, day 1 pain, and epithelial healing time between treatments. Epithelial laser in situ keratomileusis (epi-LASIK) had statistically significantly higher pain scores on day 3 compared to photorefractive keratectomy (PRK) (weighted mean differences [WMD] = 2.2, 95% credible intervals [CrI] = 0.19 to 4.01) and transepithelial PRK (T-PRK) (WMD = 2.7, 95% CrI = 0.51 to 4.84). The surface under the cumulative ranking curve ranking results (best to worst) showed laser epithelial keratomileusis (LASEK) ranked highest for efficacy, predictability, safety, and day 1 pain scores. Epi-LASIK ranked best for grade 1 haze scores. T-PRK ranked best for haze of 0.5 or higher, haze scores day 3 pain scores, and epithelial healing time.
CONCLUSIONS: Surface laser refractive surgeries are comparable in terms of efficacy, predictability, safety, and postoperative haze except for day 3 pain scores, with epi-LASIK being more painful compared to PRK and T-PRK. [J Refract Surg. 2018;34(11):726-735.].
© 2018 Wen, Tu, Flitcroft, et al.

Entities:  

Mesh:

Year:  2018        PMID: 30428092     DOI: 10.3928/1081597X-20180905-01

Source DB:  PubMed          Journal:  J Refract Surg        ISSN: 1081-597X            Impact factor:   3.573


  5 in total

1.  Fellow eye comparison between alcohol-assisted and single-step transepithelial photorefractive keratectomy: late mid-term outcomes.

Authors:  Alexander Harold Rodriguez; Virgilio Galvis; Alejandro Tello; Margarita María Parra; Marcela Ángela Rojas; Mosquera Samuel Arba; Anthony Paul Camacho
Journal:  Rom J Ophthalmol       Date:  2020 Apr-Jun

2.  Plasma rich in growth factors versus Mitomycin C in photorefractive keratectomy.

Authors:  Ronald M Sanchez-Avila; Edmar E Uribe-Badillo; Javier Fernández-Vega Sanz; Francisco Muruzabal; Nancy Jurado; Belén Alfonso-Bartolozzi; Jose F Alfonso; Begoña Baamonde; Eduardo Anitua; Jesus Merayo-Lloves
Journal:  Medicine (Baltimore)       Date:  2021-01-22       Impact factor: 1.889

3.  Establishing a Porcine Eye Model for Manual Sub-Bowman Layer Photorefractive Keratomileusis.

Authors:  Mingxia Tian; Ping Ma; Guoying Mu; Lijing Chen; Jie Feng
Journal:  J Ophthalmol       Date:  2020-07-14       Impact factor: 1.909

4.  Three-Year Outcomes of Implantable Collamer Lens Followed by Excimer Laser Enhancement ("Bioptics") in the Treatment of High Myopic Astigmatism.

Authors:  Samir Jabbour; Kraig S Bower
Journal:  Clin Ophthalmol       Date:  2021-02-16

5.  Efficacy and safety of single-step transepithelial photorefractive keratectomy with the all-surface laser ablation SCHWIND platform without mitomycin-C for high myopia: A retrospective study of 69 eyes.

Authors:  Jean Baptiste Giral; Florian Bloch; Maxime Sot; Yinka Zevering; Arpine El Nar; Jean Charles Vermion; Christophe Goetz; Louis Lhuillier; Jean-Marc Perone
Journal:  PLoS One       Date:  2021-12-07       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.